Screener
Travere Therapeutics, Inc. TVTX Business Segments — Royalty expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of goods sold | 1,950 | 4,679 |
| Research and development | 57,094 | 46,889 |
| Selling, general and administrative | 80,254 | 60,413 |
| Royalty expense | 24,816 | 12,425 |
| Total operating expenses | 164,114 | 124,406 |
| Operating loss | (36,915) | (42,674) |
| Other income, net: | ||
| Interest income | 2,584 | 3,795 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s business segments — royalty expense?
- Travere Therapeutics, Inc. (TVTX) reported business segments — royalty expense of $24.82M in Q1 2026.
- What does business segments — royalty expense mean?
- This metric represents the contractual payments made to third parties based on the sales of licensed products or intellectual property. It indicates the impact of external licensing agreements on the company's overall product profitability.
Ask your AI about Travere Therapeutics, Inc.'s business segments — royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude